APELLIS PHARMACEUTICALS INC. - COMMON STOCK

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023

05 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration

02 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023

25 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

30 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success

29 Aug 2023 06:58:00 By Nasdaq GlobeNewswire

Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE® (pegcetacoplan injection)

22 Aug 2023 16:43:29 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Aug 2023 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results

31 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)

30 Jul 2023 13:00:40 By Nasdaq GlobeNewswire

Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy

29 Jul 2023 14:52:12 By Nasdaq GlobeNewswire

Apellis Announces Seven Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

10 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Jul 2023 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

07 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Jun 2023 16:05:00 By Nasdaq GlobeNewswire

Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS

25 May 2023 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 May 2023 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results

04 May 2023 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference

03 May 2023 07:00:01 By Nasdaq GlobeNewswire